Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IDXX 
IDEXX Laboratories Inc (IDXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IDXX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $695.09
1 Year Target Price $695.09
| 3 | Strong Buy |
| 3 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.65% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 51.77B USD | Price to earnings Ratio 53.78 | 1Y Target Price 695.09 |
Price to earnings Ratio 53.78 | 1Y Target Price 695.09 | ||
Volume (30-day avg) 13 | Beta 1.5 | 52 Weeks Range 356.14 - 688.12 | Updated Date 08/28/2025 |
52 Weeks Range 356.14 - 688.12 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 12.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When Before Market | Estimate 3.3 | Actual 3.5 |
Profitability
Profit Margin 24.41% | Operating Margin (TTM) 33.62% |
Management Effectiveness
Return on Assets (TTM) 23.26% | Return on Equity (TTM) 64.87% |
Valuation
Trailing PE 53.78 | Forward PE 51.28 | Enterprise Value 52838114158 | Price to Sales(TTM) 12.82 |
Enterprise Value 52838114158 | Price to Sales(TTM) 12.82 | ||
Enterprise Value to Revenue 13.09 | Enterprise Value to EBITDA 37.75 | Shares Outstanding 80004704 | Shares Floating 79116642 |
Shares Outstanding 80004704 | Shares Floating 79116642 | ||
Percent Insiders 0.68 | Percent Institutions 97.5 |
Upturn AI SWOT
IDEXX Laboratories Inc
Company Overview
History and Background
IDEXX Laboratories, Inc. was founded in 1983 by David Shaw. It began by developing diagnostic tests for livestock and expanded into companion animal diagnostics. It has grown through organic growth and acquisitions, becoming a leading global provider of pet healthcare innovation.
Core Business Areas
- Companion Animal Group (CAG): Develops, manufactures, and distributes diagnostic and information management products and services for veterinarians, including in-clinic diagnostic instruments, reference laboratory services, and point-of-care testing.
- Water Quality Products: Offers testing solutions for detecting and quantifying various microbiological and chemical parameters in water. This includes products for drinking water, wastewater, recreational water, and environmental monitoring.
- Livestock, Poultry and Dairy (LPD): Provides diagnostic tests and related products for livestock, poultry and dairy industries to improve animal health and productivity.
Leadership and Structure
IDEXX is led by Jay Mazelsky, President and Chief Executive Officer. The organizational structure is hierarchical, with various divisions reporting to executive leadership.
Top Products and Market Share
Key Offerings
- SNAP Tests: Point-of-care diagnostic tests for various animal diseases, with significant market share in the companion animal diagnostic market. Competitors include Zoetis and Heska.
- Catalyst Dx Chemistry Analyzer: In-clinic chemistry analyzer used by veterinarians for routine bloodwork. Competitors include Abaxis (now part of Zoetis) and Heska.
- Reference Laboratories: Diagnostic testing services performed in centralized laboratories. IDEXX holds a significant market share in the veterinary reference laboratory market. Competitors include Antech Diagnostics (VCA/Mars).
- Water Microbiology Testing Products: Testing solutions for detecting and quantifying various microbiological parameters in water. Market share is considerable. Competitors include Thermo Fisher Scientific and bioMu00e9rieux.
Market Dynamics
Industry Overview
The animal health and water quality industries are experiencing growth driven by increasing pet ownership, greater awareness of preventative care, concerns about water safety, and technological advancements in diagnostics.
Positioning
IDEXX holds a leading position in the companion animal diagnostics and water quality testing markets, with a strong brand reputation, extensive distribution network, and innovative product portfolio.
Total Addressable Market (TAM)
The global animal health market is estimated to be over $50 billion. The water quality testing market is estimated to be over $4 billion. IDEXX is well-positioned to capture a significant share of these markets.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Extensive distribution network
- Innovative product portfolio
- Leading market share in key segments
- Recurring revenue model
Weaknesses
- High valuation
- Dependence on veterinary spending
- Geographic concentration of revenue
- Price competition from generics and smaller players
Opportunities
- Expansion into emerging markets
- Development of new diagnostic technologies
- Partnerships with veterinary practices and distributors
- Growth in pet insurance adoption
- Increased focus on preventative care
Threats
- Economic downturns impacting pet spending
- Increased competition from established and emerging players
- Regulatory changes in the animal health industry
- Disruptive technologies
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- ZTS
- VCA
- PKI
- BIO
Competitive Landscape
IDEXX enjoys a competitive advantage due to its extensive distribution network and innovative product portfolio. However, competitors like Zoetis offer a broader range of products and services, while smaller players may compete on price.
Major Acquisitions
ezyVet Limited
- Year: 2021
- Acquisition Price (USD millions): 168
- Strategic Rationale: Expansion into cloud-based practice management software for veterinarians.
Growth Trajectory and Initiatives
Historical Growth: IDEXX has experienced consistent revenue and earnings growth over the past decade, driven by increasing demand for its products and services.
Future Projections: Analysts project continued revenue and earnings growth for IDEXX, driven by favorable industry trends and the company's strong competitive position. The revenue growth rate is expected to remain at 10%.
Recent Initiatives: Recent strategic initiatives include expansion into new geographies, development of new diagnostic tests, and partnerships with veterinary practices and distributors.
Summary
IDEXX Laboratories is a strong company with a leading position in the animal diagnostics market. Its innovative product portfolio and extensive distribution network contribute to consistent growth. However, the high valuation and reliance on veterinary spending are key risk to watch out for. Expanding into emerging markets and focus on preventative care may further bolster its position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- IDEXX Laboratories Inc. SEC Filings (10-K, 10-Q), Investor Presentations, Market Research Reports, Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are based on available estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IDEXX Laboratories Inc
Exchange NASDAQ | Headquaters Westbrook, ME, United States | ||
IPO Launch date 1991-06-21 | President, CEO & Director Mr. Jonathan J. Mazelsky | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.idexx.com |
Full time employees 11000 | Website https://www.idexx.com | ||
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.